BioCentury
ARTICLE | Company News

CRISPR names EVP and head of R&D

August 1, 2017 11:41 PM UTC

Gene editing company CRISPR Therapeutics AG (NASDAQ:CRSP) named Tony Ho EVP and head of R&D as the company moves closer to the clinic. Ho was SVP and head of oncology integration and innovation at AstraZeneca plc (LSE:AZN; NYSE:AZN).

CRISPR President and CBO Sam Kulkarni told BioCentury that Ho will "define the next phase of growth for our R&D." The company's lead program, CTX001, is an autologous therapy targeting beta thalassemia and sickle cell disease. Kulkarni said the company plans to file a CTA in Europe for the candidate by the end of the year. ...

BCIQ Company Profiles

CRISPR Therapeutics AG